In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Pliant Therapeutics (PLRX – Research Report), with a price target of $40.00. The company’s shares closed yesterday at $17.21.
Rahimi covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Crinetics Pharmaceuticals, and CymaBay Therapeutics. According to TipRanks, Rahimi has an average return of 12.9% and a 42.29% success rate on recommended stocks.
Pliant Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $42.27, a 145.61% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $48.00 price target.
See the top stocks recommended by analysts >>
Based on Pliant Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $41.49 million. In comparison, last year the company earned a revenue of $1.48 million and had a GAAP net loss of $30.62 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pliant Therapeutics (PLRX) Company Description:
Pliant Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Its lead product candidate, PLN-74809, is an oral small-molecule dual that helps in the treatment of idiopathic pulmonary fibrosis.
Read More on PLRX:
- 3 Best Stocks to Buy Now, 2/28/2024, According to Top Analysts
- Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results
- Pliant Therapeutics price target lowered to $43 from $48 at Canaccord
- Pliant Therapeutics price target lowered to $47 from $49 at Oppenheimer
- Pliant Therapeutics Achieves Success in Liver Disease Trial
